Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on January 3, 2017. The filing reports a corporate governance event: the appointment of a new director and committee member by the Board of Directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The primary material change is the appointment of Steven H. Stein, M.D., to the Board of Directors. Dr. Stein was also appointed to the Nominating Committee and the Compensation Committee. His term expires at the next annual meeting of stockholders.
Compensation and Governance Details
- Cash Retainer: Dr. Stein will receive an annual cash retainer of $35,000 for Board service, plus $3,750 for the Nominating Committee and $5,000 for the Compensation Committee.
- Equity Grants:
- 30,000 shares of common stock options vesting annually over three years.
- 3,333 shares of common stock options vesting in full on the one-year anniversary of the grant date.
- Future automatic annual grants of 10,000 shares on the date of each annual meeting, vesting in full one year later.
- Change in Control: All option grants vest in full upon a change in control.
- Indemnification: Dr. Stein has entered into the Company's standard Indemnification Agreement.
Investor Verification Checklist
- Verify Dr. Stein's professional background and potential conflicts of interest.
- Review the Company's equity incentive plan to confirm the valuation and terms of the granted options.
- Check the date of the next annual meeting of stockholders to determine the expiration of Dr. Stein's initial term.
- Confirm the total number of authorized shares available for issuance under the equity plan to assess dilution impact.